Hasil Pencarian - Hanrui Chen

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    ECFuse: Edge-Consistent and Correlation-Driven Fusion Framework for Infrared and Visible Image Fusion

    ECFuse: Edge-Consistent and Correlation-Driven Fusion Framework for Infrared and Visible Image Fusion oleh Hanrui Chen, Lei Deng, Lianqing Zhu, Mingli Dong

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Posterior reversible encephalopathy syndrome associated with use of anlotinib to treat squamous cell carcinoma of the cervix: case report and literature review

    Posterior reversible encephalopathy syndrome associated with use of anlotinib to treat squamous cell carcinoma of the cervix: case report and literature review oleh Jietao Lin, Jietao Lin, Wenmin Chen, Sha Zhong, Kai Qian, Hanrui Chen, Lizhu Lin

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review

    Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review oleh Xiangjun Qi, Jiayun Guo, Xiaoqi Zhou, Lingling Sun, Jietao Lin, Zijing Huang, Hanrui Chen, Lizhu Lin

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

    Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review oleh Ruiting Lin, Ruilian Chen, Zhiqiang Chen, Leihao Hu, Wei Guo, Zexin Zhang, Lizhu Lin, Hanrui Chen

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement

    Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement oleh Ling Yu, Jietao Lin, Hanhan Li, Lingling Sun, Shubo Wang, Yaoxu Chen, Hanrui Chen, Lizhu Lin

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report

    A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report oleh Jietao Lin, Ling Yu, Yuanfeng Fu, Hanrui Chen, Xinting Zheng, Shutang Wang, Chan Gao, Yang Cao, Lizhu Lin

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)

    Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Inte... oleh Jietao Lin MD, Lingling Sun MD, Hanrui Chen MD, Wenmin Chen MM, Zexin Zhang MM, Yang Cao MD, Lizhu Lin MD

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K/Akt/P53/FoxO signaling axis

    Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K/Akt/P... oleh Wei Guo, Xiaohui Yao, Siyuan Lan, Chi Zhang, Hanhan Li, Zhuangzhong Chen, Ling Yu, Guanxian Liu, Yuan Lin, Shan Liu, Hanrui Chen

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway

    Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway oleh Xiaozhong Liao, Lanting Tao, Wei Guo, Zhuo-Xun Wu, Haiyan Du, Jing Wang, Jue Zhang, Hanrui Chen, Zhe-Sheng Chen, Lizhu Lin, Lingling Sun

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study

    Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Ra... oleh Wenmin Chen MM, Jietao Lin MD, Ting Yang MM, Ze xin Zhang MM, Lanting Tao MD, Zhiwei Xiao MD, Hanrui Chen MM, Xiangjun Qi MM, Lingling Sun MD, Yang Cao MD, Lizhu Lin MD

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: